BMS 493
SIGMA/B6688 - ≥98% (HPLC)
Synonym: (E)
CAS Number: 215030-90-3
Empirical Formula (Hill Notation): C29H24O2
Molecular Weight: 404.50
MDL Number: MFCD17215944
Linear Formula: C29H24O2
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | light yellow to yellow |
| form | powder |
| InChI | 1S/C29H24O2/c1-29(2)19-18 |
| InChI key | YCADIXLLWMXYKW-CMDGGOBGSA |
| originator | Bristol-Myers Squibb |
| Quality Level | 100  |
| SMILES string | CC1(C)CC=C(C#Cc2ccccc2)c3 |
| solubility | DMSO: ≥20 mg/mL |
| storage temp. | 2-8°C |
| Application: | BMS 493 has been used: • as an inhibitor for the dietary and pharmacologic manipulation of retinoic acid (RA) activity in vivo and in vitro • for human induced pluripotent stem cells (iPSCs) culture and ventricular cardiomyocytes (VCMs) differentiation • to inhibit retinoic acid (RA) signaling in explants • as a retinoic acid receptor (RAR) inhibitor for the induction of synaptonemal complex protein 3 (SCP3) and ATP-dependent RNA helicase (DDX4) in primordial germ cells (PGCs) |
| Biochem/physiol Actions: | BMS 493 is an inverse pan-RAR agonist. |
| Biochem/physiol Actions: | BMS 493 is an inverse pan-RAR agonist. Retinoic acid receptors (RARs) are ligand-dependent transcription factors that control a number of physiological processes. RARs exert their functions by regulating gene networks controlling cell growth, differentiation, survival, and death. |
| Features and Benefits: | This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm . |
| Features and Benefits: | This compound is featured on the Nuclear Receptors (Non-Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Features and Benefits: | This compound was developed by Bristol-Myers Squibb . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| General description: | BMS 493 inhibits the formation of neuritic processes and plasmenyethanolamine -phospholipase A2 (PLA2) activity. |
| Packaging: | 5, 25 mg in glass bottle |
| Hazard statements | H413 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 2 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |